Recent developments and perspectives on gene therapy using synthetic vectors

Therapeutic Delivery

Volumn 4, Issue 1, 2013, Pages 95-113

  Schlenk, Florian ^a   Grund, Stefan ^a   Fischer, Dagmar ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPOGENE TIPARVOVEC; ALPHA2B INTERFERON; ANTISENSE OLIGONUCLEOTIDE; BETA GALACTOSIDASE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DENDRIMER; DEOXYRIBONUCLEASE; DEXTRAN; DRUG CARRIER; EPIDERMAL GROWTH FACTOR; EPSTEIN BARR VIRUS ANTIGEN 1; HETASTARCH; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; INTERLEUKIN 12; LIPID; LIPOFECTIN; MACROGOL; NAKED DNA; NUCLEIC ACID; PLASMID DNA; POLYAMIDOAMINE; POLYMER; RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SYNTHETIC DNA; SYNTHETIC RNA; SYNTHETIC VECTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN 165;

BIODEGRADABILITY; BIOMEDICINE; BIOTECHNOLOGY; CELL COMPARTMENTALIZATION; CONTROLLED RELEASE FORMULATION; DISEASE SEVERITY; DNA FRAGMENTATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; ENDOSOME; FREEZE DRYING; GENE THERAPY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GOOD MANUFACTURING PRACTICE; HUMAN; INTRACELLULAR TRANSPORT; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PANCREATITIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE;

EID: 84871592382     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.128     Document Type: Review

References (109)

1. Grund S, Bauer M, Fischer D. Polymers in drug delivery-state of the art and future trends. Adv. Eng. Mat. 13(3), B61-B87 (2011).
2. Hunter AC, Moghimi SM. Therapeutic synthetic polymers: a game of Russian roulette? Drug Discov. Today 7(19), 998-1001 (2002).
3. Sivalingam J, Kon OL. Recent advances and improvements in the biosafety of gene therapy. In: Gene Therapy-Developments and Future Perspectives. Kang C (Ed. ). Intech, NY, USA, 145-188 (2011).
4. U. S. Department of Health and Human Services, FDA, Center for Biologics Evaluation and Research. Gene therapy clinical trials-observing subjects for delayed adverse events. (2006).
5. Avery OT, Macleod CM, Mccarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J. Exp. Med. 79(2), 137-158 (1944).
6. Yla-Herttuala S, Wirth T. Therapeutic delivery using gene-delivery methods. Ther. Deliv. 2(4), 423-426 (2011).
7. Kohn DB, Candotti F. Gene therapy fulfilling its promise. N. Engl. J. Med. 360(5), 518-521 (2009).
8. Boeckle S, Wagner E. Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems. AAPS J. 8(4), E731-E742 (2006).
9. Zhu L, Mahato RI. Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin. Drug Deliv. 7(10), 1209-1226 (2010).
10. Nguyen J, Szoka FC. Nucleic acid delivery. the missing pieces of the puzzle? Acc. Chem. Res. 45(7), 1153-1162 (2012).
11. Pagano JS, Vaheri A. Enhancement of infectivity of poliovirus RNA with diethylaminoethyl-dextran (DEAE-D). Arch. Virol. 17(3), 456-464 (1965).
12. Felgner PL, Gadek TR, Holm M et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl Acad. Sci. USA 84(21), 7413-7417 (1987).
13. Lu ZR. Stability of proteins and nucleic acids. Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids. Mahato RI (Ed. ) CRC Press, Fl, USA, 352-374 (2005).
14. Lindahl T. Instability and decay of the primary structure of DNA. Nature 362(6422), 709-715 (1993).
15. Fischer D, Dautzenberg H, Kunath K, Kissel T. Poly(diallyldimethylammonium chlorides) and their N-methyl-N-vinylacetamide copolymer-based DNA-polyplexes: role of molecular weight and charge density in complex formation, stability, and in vitro activity. Int. J. Pharm. 280(1-2), 253-269 (2004).
16. Adami RC, Collard WT, Gupta SA, Kwok KY, Bonadio J, Rice KG. Stability of peptide-condensed plasmid DNA formulations. J. Pharm. Sci. 87(6), 678-683 (1998).
17. Anchordoquy TJ, Koe GS. Physical stability of nonviral plasmid-based therapeutics. J. Pharm. Sci. 89(3), 289-296 (2000).
18. Armitage B. Photocleavage of nucleic acids. Chem. Rev. 98(3), 1171-1200 (1998).
19. Pogocki D, Schoneich C. Chemical stability of nucleic acid-derived drugs. J. Pharm. Sci. 89(4), 443-456 (2000).
20. Oh YK, Kim JP, Yoon H, Kim JM, Yang JS, Kim CK. Prolonged organ retention and safety of plasmid DNA administered in polyethylenimine complexes. Gene Ther. 8(20), 1587-1592 (2001).
21. Takakura Y, Nishikawa M, Yamashita F, Hashida M. Development of gene drug delivery systems based on pharmacokinetic studies. Eur. J. Pharm. Sci. 13(1), 71-76 (2001).
22. Ward CM, Read ML, Seymour LW. Systemic circulation of poly(L-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy. Blood 97(8), 2221-2229 (2001).
23. Fischer D. In vivo fate of polymeric gene carriers. Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids. Mahato RI (Ed. ) CRC Press, Fl, USA, 295-314 (2005).
24. Vaughan EE, Degiulio JV, Dean DA. Intracellular trafficking of plasmids for gene therapy: mechanisms of cytoplasmic movement and nuclear import. Curr. Gene Ther. 6(6), 671-681 (2006).
25. Lukacs GL, Haggie P, Seksek O, Lechardeur D, Freedman N, Verkman AS. Size-dependent DNA mobility in cytoplasm and nucleus. J. Biol. Chem. 275(3), 1625-1629 (2000).
26. Dauty E, Verkman AS. Actin cytoskeleton as the principal determinant of size-dependent DNA mobility in cytoplasm: a new barrier for non-viral gene delivery. J. Biol. Chem. 280(9), 7823-7828 (2005).
27. Pollard H, Toumaniantz G, Amos JL et al. Ca2+-sensitive cytosolic nucleases prevent efficient delivery to the nucleus of injected plasmids. J. Gene Med. 3(2), 153-164 (2001).
28. James MB, Giorgio TD. Nuclear-associated plasmid, but not cell-associated plasmid, is correlated with transgene expression in cultured mammalian cells. Mol. Ther. 1(4), 339-346 (2000).
29. Xu L, Anchordoquy T. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J. Pharm. Sci. 100(1), 38-52 (2011).
30. Golan R, Pietrasanta LI, Hsieh W, Hansma HG. DNA toroids: stages in condensation. Biochemistry 38(42), 14069-14076 (1999).
31. Hansma HG, Golan R, Hsieh W, Lollo CP, Mullen-Ley P, Kwoh D. DNA condensation for gene therapy as monitored by atomic force microscopy. Nucleic Acids Res. 26(10), 2481-2487 (1998).
32. Patel MM, Anchordoquy TJ. Contribution of hydrophobicity to thermodynamics of ligand-DNA binding and DNA collapse. Biophys. J. 88(3), 2089-2103 (2005).
33. Sunshine JC, Bishop CJ, Green JJ. Advances in polymeric and inorganic vectors for nonviral nucleic acid delivery. Ther. Deliv. 2(4), 493-521 (2011).
34. Neu M, Fischer D, Kissel T. Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. J. Gene Med. 7(8), 992-1009 (2005).
35. Tang R, Palumbo RN, Nagarajan L, Krogstad E, Wang C. Well-defined block copolymers for gene delivery to dendritic cells: probing the effect of polycation chain-length. J. Control. Release 142(2), 229-237 (2010).
36. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 24(7), 1121-1131 (2003).
37. Godbey WT, Wu KK, Mikos AG. Size matters: Molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle J. Biomed. Mater. Res. 45(3), 268-275 (1999
38. Guo X, Huang L. Recent advances in nonviral vectors for gene delivery. Acc. Chem. Res. 45(7), 971-979 (2012).
39. Balazs DA, Godbey W. Liposomes for use in gene delivery. J. Drug Del. 2011, 326497 (2011).
40. Behr J-P. Synthetic gene transfer vectors II: back to the future. Acc. Chem. Res. 45(7), 980-984 (2012).
41. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 49(36), 6288-6308 (2010).
42. Barz M, Luxenhofer R, Zentel R, Vicent MJ. Overcoming the PEG-addiction: well-defined alternatives to PEG, from structure-property relationships to better defined therapeutics. Polymer Chem. 2(9), 1900-1918 (2011).
43. Bauer M, Lautenschlaeger C, Kempe K, Tauhardt L, Schubert US, Fischer D. Poly(2-ethyl-2-oxazoline) as alternative for the stealth polymer poly(ethylene glycol): comparison of in vitro cytotoxicity and hemocompatibility. Macromol. Biosci. 12(7), 986-998 (2012).
44. Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J. Control. Release 161(2), 461-472 (2012
45. Wagner E. Polymers for siRNA Delivery: inspired by viruses to be targeted, dynamic, and precise. Acc. Chem. Res. 45(7), 1005-1013 (2012).
46. Walker GF, Fella C, Pelisek J et al. Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. Mol. Ther. 11(3), 418-425 (2005).
47. Rozema DB, Lewis DL, Wakefield DH et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl Acad. Sci. USA 104(32), 12982-12987 (2007).
48. Noga M, Edinger D, Rodl W, Wagner E, Winter G, Besheer A. Controlled shielding and deshielding of gene delivery polyplexes using hydroxyethyl starch (HES) and alpha-amylase. J. Control. Release 159(1), 92-103 (2012).
49. Wu C, Belenda C, Leroux JC, Gauthier MA. Interplay of chemical microenvironment and redox environment on thiol-disulfide exchange kinetics. Chemistry 17(36), 10064-10070 (2011).
50. Bauhuber S, Hozsa C, Breunig M, Gopferich A. Delivery of nucleic acids via disulfide-based carrier systems. Adv. Mater. 21(32-33), 3286-3306 (2009).
51. Zhang G, Liu J, Yang Q, Zhuo R, Jiang X. Disulfide-containing brushed polyethylenimine derivative synthesized by click chemistry for nonviral gene delivery. Bioconjug. Chem. 23(6), 1290-1299 (2012).
52. Peng Q, Zhong Z, Zhuo R. Disulfide cross-linked polyethylenimines (PEI) prepared via thiolation of low molecular meight PEI as highly efficient gene vectors. Bioconjug. Chem. 19(2), 499-506 (2008).
53. Brülisauer L, Leroux JC. Disulfide reduction considerations for cationic gene delivery systems. Presented at: CRS Annual Meeting Abstracts. Québec City, Canada, 15-18 July 2012.
54. Ogris M, Wagner E. To be targeted: is the magic bullet concept a viable option for synthetic nucleic acid therapeutics? Hum. Gene Ther. 22(7), 799-807 (2011).
55. Basile L, Pignatello R, Passirani C. Active targeting strategies for anticancer drug nanocarriers. Curr. Drug Deliv. 9(3), 255-268 (2012).
56. Breunig M, Bauer S, Goepferich A. Polymers and nanoparticles: intelligent tools for intracellular targeting? Eur. J. Pharm. Sci. 68(1), 112-128 (2008).
57. Butler LM, Mcgettrick HM, Nash GB. Static and dynamic assays of cell adhesion relevant to the vasculature. Methods Mol. Biol. 467, 211-228 (2009).
58. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6(3), 659-668 (2009).
59. Nakase I, Akita H, Kogure K et al. Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides. Acc. Chem. Res. 45(7), 1132-1139 (2012).
60. Wang DA, Narang AS, Kotb M et al. Novel branched poly(ethylenimine)- cholesterol water-soluble lipopolymers for gene delivery. Biomacromolecules 3(6), 1197-1207 (2002).
61. Jones SP, Gabrielson NP, Pack DW, Smith DK. Synergistic effects in gene delivery-a structure-activity approach to the optimisation of hybrid dendritic-lipidic transfection agents. Chem. Commun. 39, 4700-4702 (2008).
62. Han S, Mahato RI, Kim SW. Water-soluble lipopolymer for gene delivery. Bioconjug. Chem. 12(3), 337-345 (2001).
63. Santos JL, Oliveira H, Pandita D et al. Functionalization of poly(amidoamine) dendrimers with hydrophobic chains for improved gene delivery in mesenchymal stem cells. J. Control. Release 144(1), 55-64 (2010).
64. Xu Y, Szoka FC Jr. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 35(18), 5616-5623 (1996).
65. Cullis PR, Hope MJ, Tilcock CP. Lipid polymorphism and the roles of lipids in membranes. Chem. Phys. Lipids 40(2-4), 127-144 (1986).
66. Zelphati O, Szoka FC, Jr. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl Acad. Sci. USA 93(21), 11493-11498 (1996).
67. Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 8(15), 1188-1196 (2001).
68. Behr JP. The proton sponge: a trick to enter cells the viruses did not exploit. CHIMIA 51(1-2), 34-36 (1997).
69. Yang S, May S. Release of cationic polymer-DNA complexes from the endosome: a theoretical investigation of the proton sponge hypothesis. J. Chem. Phys. 129(18), 185105 (2008).
70. Fischer D, Von Harpe A, Kunath K, Petersen H, Li Y, Kissel T. Copolymers of ethylene imine and N-(2-hydroxyethyl)-ethylene imine as tools to study effects of polymer structure on physicochemical and biological properties of DNA complexes. Bioconjug. Chem. 13(5), 1124-1133 (2002).
71. Martin ME, Rice KG. Peptide-guided gene delivery. AAPS J. 9(1), E18-E29 (2007).
72. Berg K, Folini M, Prasmickaite L et al. Photochemical internalization: a new tool for drug delivery. Curr. Pharm. Biotechnol. 8(6), 362-372 (2007).
73. Zhang Y, Anchordoquy TJ. The role of lipid charge density in the serum stability of cationic lipid/DNA complexes. Biochim. Biophys. Acta 1663(1-2), 143-157 (2004).
74. Templeton NS. Cationic liposomes as in vivo delivery vehicles. Curr. Med. Chem. 10(14), 1279-1287 (2003).
75. Wang F, Weaver VM, Petersen OW et al. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc. Natl. Acad. Sci. USA 95(25), 14821-14826 (1998).
76. Dinh AT, Pangarkar C, Theofanous T, Mitragotri S. Understanding intracellular transport processes pertinent to synthetic gene delivery via stochastic simulations and sensitivity analyses. Biophys. J. 92(3), 831-846 (2007).
77. Zhang H, Lee MY, Hogg MG, Dordick JS, Sharfstein ST. Gene delivery in three-dimensional cell cultures by superparamagnetic nanoparticles. ACS Nano 4(8), 4733-4743 (2010).
78. Abbott A. Cell culture: biology's new dimension. Nature 424(6951), 870-872 (2003).
79. Hodges BL, Taylor KM, JosepH MF, Bourgeois SA, Scheule RK. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol. Ther. 10(2), 269-278 (2004).
80. Chen ZY, He CY, Meuse L, Kay MA. Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther. 11(10), 856-864 (2004).
81. Schleef M. DNA-Pharmaceuticals. Wiley-Vch, Bielefeld, Germany (2005).
82. Boussif O, Lezoualc'h F, Zanta MA et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA 92(16), 7297-7301 (1995).
83. Beck-Broichsitter M, Ruppert C, Schmehl T et al. Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro. Nanomedicine 7(3), 341-350 (2011).
84. Gebhart CL, Kabanov AV. Evaluation of polyplexes as gene transfer agents. J. Control. Release 73(2-3), 401-416 (2001).
85. Schaffert D, Wagner E. Gene therapy progress and prospects: synthetic polymer-based systems. Gene Ther. 15(16), 1131-1138 (2008).
86. Clement J, Kiefer K, Kimpfler A, Garidel P, Peschka-Süss R. Large-scale production of lipoplexes with long shelf-life. Eur. J. Pharm. Biopharm. 59(1), 35-43 (2005).
87. Suh J, Paik HJ, Hwang BK. Ionization of poly(ethylenimine) and poly(allylamine) at various pHs. Bioorg. Chem. 22(3), 318-327 (1994).
88. Kabanov VA, Kabanov AV. Interpolyelectrolyte and block ionomer complexes for gene delivery: physico-chemical aspects. Adv. Drug Deliv. Rev. 30(1-3), 49-60 (1998).
89. Bronich T, Kabanov AV, Marky LA. A thermodynamic characterization of the interaction of a cationic copolymer with DNA. J. Phys. Chem. B 105(25), 6042-6050 (2001).
90. Mahato R, Furgeson D, Maheshwari A, et al. Polymeric gene delivery for cancer treatment. In: Biomaterials and Drug Delivery Towards New Millenium. Park KD, Kwon IC, Yui N, Jeong SY, Park K (Eds. ). Han Rim Wonn Publishing, 249-280 (2000).
91. Clamme JP, Azoulay J, Mely Y. Monitoring of the formation and dissociation of polyethylenimine/DNA complexes by two photon fluorescence correlation spectroscopy. Biophys. J. 84(3), 1960-1968 (2003).
92. Boeckle S, Von Gersdorff K, Van Der Piepen S, Culmsee C, Wagner E, Ogris M. Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J. Gene Med. 6(10), 1102-1111 (2004).
93. Zelphati O, Nguyen C, Ferrari M, Felgner J, Tsai Y, Felgner PL. Stable and monodisperse lipoplex formulations for gene delivery. Gene Ther. 5(9), 1272-1282 (1998).
94. Kasper JC, Schaffert D, Ogris M, Wagner E, Friess W. Development of a lyophilized plasmid/LPEI polyplex formulation with long-term stability-a step closer from promising technology to application. J. Control. Release 151(3), 246-255 (2011).
95. Debus H, Beck-Broichsitter M, Kissel T. Optimized preparation of pDNA/poly(ethylene imine) polyplexes using a microfluidic system. Lab. Chip 12(14), 2498-2506 (2012).
96. Kasper JC, Schaffert D, Ogris M, Wagner E, Friess W. The establishment of an up-scaled micro-mixer method allows the standardized and reproducible preparation of well-defined plasmid/LPEI polyplexes. Eur. J. Pharm. Biopharm. 77(1), 182-185 (2011).
97. Knight JB, Vishwanath A, Brody JP, Austin RH. Hydrodynamic focusing on a silicon chip: mixing nanoliters in microseconds. Phys. Rev. Lett. 80(17), 3863-3866 (1998).
98. Koh CG, Kang X, Xie Y et al. Delivery of polyethylenimine/DNA complexes assembled in a microfluidics device. Mol. Pharm. 6(5), 1333-1342 (2009).
99. Talsma H, Cherng J, Lehrmann H et al. Stabilization of gene delivery systems by freeze-drying. Int. J. Pharm. 157(2), 233-238 (1997).
100. Huang YC, Connell M, Park Y, Mooney DJ, Rice KG. Fabrication and in vitro testing of polymeric delivery system for condensed DNA. J. Biomed. Mater. Res. A 67(4), 1384-1392 (2003).
101. Pfeifer C, Hasenpusch G, Uezguen S et al. Dry powder aerosols of polyethylenimine (PEI)-based gene vectors mediate efficient gene delivery to the lung. J. Control. Release 154(1), 69-76 (2011).
102. Ma G, Shimada H, Hiroshima K, Tada Y, Suzuki N, Tagawa, M. Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China. Drug Des. Devel. Ther. 2(1), 115-122 (2008).
103. Eastman SJ, Siegel C, Tousignant J, Smith AE, Cheng SH, Scheule RK. Biophysical characterization of cationic lipid: DNA complexes. Biochim. Biophysica. Acta. Biomembranes 1325(1), 41-62 (1997).
104. Eastman SJ, Tousignant JD, Lukason MJ, Chu Q, Cheng SH, Scheule RK. Aerosolization of cationic lipid:pDNA complexes-in vitro optimization of nebulizer parameters for human clinical studies. Hum. Gene Ther. 9(1), 43-52 (1998).
105. Wagner JA. Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson. Curr. Opin. Mol. Ther. 1(2), 266-270 (1999).
106. Ohana P. Regulatory sequences of the H19 gene in DNA based therapy of bladder cancer. Gene Ther. Mol. Biol. (8), 181-192 (2004).
107. Kendrick J. A Phase I trial of intraperitoneal EGEN-001, a novel IL-12 gene therapeutic, administered alone or in combination with chemotherapy in patients with recurrent ovarian cancer. J. Clin. Oncol. 26, 5572 (2008).
108. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem. Rev. 109(2), 259-302 (2009).
109. Lori F, Trocio J, Bakare N, Kelly LM, Lisziewicz J. DermaVir, a novel HIV immunisation technology. Vaccine 23(17-18), 2030-2034 (2005).